Drugs / Alnuctamab
Alnuctamab
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07219563 | Mar 2026 → Dec 2027 expected | systemic lupus erythematosus | Icahn School of Medicine at Mount Sinai | Recruiting | No outcome recorded |
| Phase 1 | NCT06163898 | Feb 2024 → Jun 2025 | plasma cell myeloma | Celgene Corporation | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT06121843 | Feb 2024 → Aug 2028 expected | plasma cell myeloma | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06232707 | May 2024 → Nov 2025 | plasma cell myeloma | Celgene Corporation | Withdrawn | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2023-12-11 | Bristol-Myers Squibb | Results Bristol Myers Squibb Announces Data at ASH 2023 from Diverse Multiple Myeloma Pipeline, Underscoring Range of Tailored Treatment Approaches to Address Unique Patient Needs bms.com ↗
Updated results of the Phase 1 study of alnuctamab, a 2+1 BCMA x CD3 bispecific TCE, show deepening and durable responses, including minimal residual disease (MRD) negativity, along with manageable safety |
| 2023-05-11 | Bristol-Myers Squibb | Results Bristol Myers Squibb to Highlight Diversified Approaches and Commitment to Improving Outcomes for Patients with Cancer and Serious Blood Disorders at ASCO, EHA and ICML 2023 bms.com ↗
Preliminary results from the dose-escalation and expansion components of the Phase 1 CC-93269-MM-001 study demonstrate subcutaneous administration of bispecific T-cell engager alnuctamab exhibited promising dose-dependent anti-tumor activity in heavily pretreated multiple myeloma, with a high proportion of responders achieving minimal residual disease negativity. |
| 2022-12-12 | Bristol-Myers Squibb | Results Bristol Myers Squibb Announces First Disclosures and New Data at ASH 2022, Demonstrating Commitment to Raising Standards in Treatment Through Broad Multiple Myeloma Portfolio bms.com ↗ |
All press releases naming this drug 3 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alnuctamab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06232707 ↗ |
| Known as | BMS-986349 | “This study will assess the safety and preliminary efficacy of the bi-specific TCE, alnuctamab (known as BMS-986349, CC-93269, EM901), targeting BCMA in patients with moderate...” NCT07219563 ↗ |
| Known as | CC-93269 | “This study will assess the safety and preliminary efficacy of the bi-specific TCE, alnuctamab (known as BMS-986349, CC-93269, EM901), targeting BCMA in patients with moderate...” NCT07219563 ↗ |
| Modality | Protein / enzyme biologic | “It is a special protein engineered in the laboratory, which is able to attach to T cells, a type of white blood cell that can kill other cells in the body.” NCT07219563 ↗ |
| Route | Subcutaneous | “The study drug will be given as an injection under the skin.” NCT07219563 ↗ |